Yakup Ergün: Full List of Oral Research Presentations at SABCS 2026
Yakup Ergün/X

Yakup Ergün: Full List of Oral Research Presentations at SABCS 2026

The San Antonio Breast Cancer Symposium (SABCS) is one of the world’s largest meetings on breast cancer. The 2026 edition, the 49th annual symposium, takes place on December 8 to 11, 2026 at the Henry B. González Convention Center in San Antonio, Texas, with both in-person and virtual participation. It is hosted by UT Health San Antonio and the American Association for Cancer Research (AACR) and directed by Carlos L. Arteaga and Virginia G. Kaklamani.

SABCS highlights the latest advances in breast cancer research and patient care, including findings from late-breaking clinical trials, with presentations on the biology, causes, prevention, diagnosis and treatment of the disease. The meeting brings together more than 11,000 physicians, researchers, clinicians and patient advocates from over 100 countries. aacr

Ahead of the meeting, the full list of presentations for SABCS 2026 is available. Yakup Ergün, Medical Oncologist at Bower Hospital, shared on X:

 

“The full list of oral research presentations at SABCS26.

Looking forward to new data and studies with the potential to change clinical practice in breast cancer.

 

General Session 1

Wednesday, 9 December 2026 | 6 research presentations

  • GS1-1 (01): External Validation of a Causal Multi-Modal AI Model for Prognosis and Chemotherapy Benefit in Node-Negative HR+/HER2- Breast Cancer Patients: Analysis of TAILORx – Nancy Chan
  • GS1-2 (02): Blinded validation of a causal multi-modal AI model in postmenopausal, node-positive, HR+ breast cancer: analysis of SWOG-8814 – Alastair M Thompson
  • GS1-4 (03): Efficacy results of the SWOG-S1418 / NRG Oncology BR006 randomized Phase III trial evaluating adjuvant Pembrolizumab for triple negative breast cancer with residual disease after neoadjuvant chemotherapy. – Lajos Pusztai
  • GS1-5 (04): Neoadjuvant Famitinib in combine with Camrelizumab and chemotherapy in Triple Negative breast cancer (BCTOP-T-N01): a multicentre, randomized, phase 3 trial – Jun-Jie Li
  • GS1-6 (05): Results of phase II NeoTRACT trial: Neoadjuvant tumor infiltrating lymphocyte- and response-adapted chemoimmunotherapy for triple-negative breast cancer (TNBC) – Priyanka Sharma
  • GS1-8 (06): First-line sacituzumab tirumotecan (sac-TMT) vs chemotherapy in unresectable recurrent or metastatic triple-negative breast cancer (TNBC) with PD-L1 CPS <10 or prior early-stage PD-(L)1 exposure: randomized phase 3 OptiTROP-Breast03 trial – Lei Fan

General Session 2

Thursday, 10 December 2026 | 4 research presentations

  • GS2-1 (07): Omission of Breast Surgery in HER2-Positive Primary Breast Cancer Achieving Clinical Complete Response After Anti-HER2-Based Therapy: Primary Results From the AMATERAS-BC Prospective Phase III Trial (JCOG1806) – Tomomi Fujisawa
  • GS2-3 (08): Prospect : post-operative radiotherapy omission in selected patients with early breast cancer trial (ANZ 1002). Final results. – Bruce Mann
  • GS2-4 (09): Neonod2 trial: initial oncologic outcomes following omission of axillary lymph node dissection in breast cancer patients with sentinel lymph node micrometastases after neoadjuvant therapy – Corrado Tinterri
  • GS2-5 (10): Results of the POSNOC Trial: Omission of Axillary Treatment in Patients Undergoing Breast-Conserving Surgery or Mastectomy with One or Two Sentinel Node Macrometastases – Amit Goyal

General Session 3

Friday, 11 December 2026 | 9 research presentations

  • GS3-1 (11): Final overall survival of imlunestrant versus standard of care in ESR1-mutated advanced breast cancer: updated efficacy from the phase 3 EMBER-3 trial – Komal L Jhaveri
  • GS3-2 (12): Camizestrant + palbociclib (palbo) vs anastrozole (ana) + palbo as upfront first-line (1L) therapy in patients (pts) with ER+/HER2- advanced breast cancer (ABC): results from the randomized phase 3 SERENA-4 trial – Fabrice André
  • GS3-4 (13): Characterization of clinical outcomes in monarchE by histologic, molecular, and genomic subtypes: Updated baseline tumor analysis from patients with HR+, HER2–, node-positive, high-risk early breast cancer – Nick Turner
  • GS3-5 (14): Longitudinal analysis of imaging biomarkers and ctDNA to predict neoadjuvant therapy response: a retrospective study from I-SPY 2 – Wen Li
  • GS3-6 (15): Translational discovery and validation of genomic alterations associated with AKT inhibitor (AKTi) resistance in hormone receptor-positive, HER2-negative metastatic breast cancer (HR+/HER2- MBC) – Maxwell R Lloyd
  • GS3-7 (16): Vaccination to target PARP inhibitor resistance caused by BRCA1/2 reversion mutations – Stephen J. Pettitt
  • GS3-8 (17): Efficacy and safety of neoadjuvant trastuzumab deruxtecan (T-DXd) monotherapy versus standard of care (SoC) therapy in stage I-II HER2+ early breast cancer (eBC): First results from WSG ADAPT-HER2-IV – Nadia Harbeck
  • GS3-9 (18): Trastuzumab rezetecan with or without pertuzumab in untreated HER2-positive recurrent or metastatic breast cancer: a multicenter, randomized phase 3 study (HORIZON-Breast07) – Yongmei Yin
  • GS3-10 (19): The STOP-HER2 Trial: A Phase 2 Study of Stopping Trastuzumab – Outcomes in Patients (pts) with HER2+ Metastatic Breast Cancer (MBC) (TBCRC 062) – Heather A Parsons

Rapid Fire 1

Tuesday, 8 December 2026 | 6 research presentations

  • RF1-1 (20): Zanidatamab as a component of neoadjuvant therapy in HER2+ breast cancer: results from the I-SPY2.2 trial – Anthony D Elias
  • RF1-2 (21): Event-free survival from the randomized phase 2 neohip trial evaluating neoadjuvant taxane, her2-targeted therapy, +/- pembrolizumab in early-stage her2-positive breast cancer – Heather L McArthur
  • RF1-3 (22): Circulating tumor DNA (ctDNA) dynamics and pathological complete response (pCR) in high-risk HER2+ early breast cancer (eBC) treated with neoadjuvant trastuzumab deruxtecan followed by paclitaxel + trastuzumab + pertuzumab (T-DXd-THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (ddAC-THP): A DESTINY-Breast11 (DB-11) analysis – Shanu Modi
  • RF1-4 (23): Optimising the duration of trastuzumab in early-stage HER2-positive breast cancer – an Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) meta-analysis – Rosie Bradley
  • RF1-5 (24): A randomized trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: First analysis of the ARIADNE trial – Theodoros Foukakis
  • RF1-6 (25): Patina (aft-38): palbociclib benefit across key prespecified subgroups in hr+/her2-positive advanced breast cancer – final protocol-specified pfs analysis – Otto Metzger

Rapid Fire 2

Tuesday, 8 December 2026 | 7 research presentations

  • RF2-1 (26): Updated Overall Survival (OS) Analysis from the Phase 3 ASCENT-07 Study of Sacituzumab Govitecan in Participants with HR+/HER2- Inoperable, Locally Advanced, or Metastatic Breast Cancer Post Endocrine Therapy – Hope S Rugo
  • RF2-2 (27): Prognostic and predictive value of key immunohistochemistry (IHC) protein biomarker expression levels in the NATALEE trial of adjuvant ribociclib (RIB) and nonsteroidal aromatase inhibitor (NSAI) in hormone receptor-positive/human epidermal growth factor receptor 2–negative early breast cancer (HR+/HER2– EBC) – Michael Press
  • RF2-3 (28): h&E-derived gene-expression multimodal multitask modeling predicts chemotherapy benefit, distant recurrence risk, and 21-gene recurrence score in tailorx – Joseph Sparano
  • RF2-4 (29): Genomic Response-Guided Chemotherapy Omission After Neoadjuvant Ribociclib and Endocrine Therapy in High-Risk HR+/HER2– Early Breast Cancer: Updated Results from the Phase II SOLTI-UNICANCER RIBOLARIS Trial – Milana Arantza Bergamino Sirvén
  • RF2-5 (30): Prospective Validation of Modified PEPI Following Neoadjuvant (Neoadj) Anastrozole (ANA): Five-Year (5y) Recurrence-free Survival (RFS) from Alliance A011106 (ALTERNATE) – Cynthia X Ma
  • RF2-6 (31): Cdk2 mediates RB-independent entry into S phase and is a therapeutic target in ER+/RB-deficient, CDK4/6 inhibitor-resistant breast cancer – Chang-Ching A Lin
  • RF2-7 (32): Results from KEYNOTE-B49: a phase 3, randomized, double-blind study of pembrolizumab (vs placebo) plus chemotherapy in participants with HR+/HER2– locally recurrent inoperable or metastatic breast cancer – Peter Schmid

Rapid Fire 3

Wednesday, 9 December 2026 | 7 research presentations

  • RF3-1 (33): Clinical validation of a multimodal model for frontline therapeutic selection in breast cancer – Luca Boscolo-Bielo
  • RF3-2 (34): A single cell and spatial atlas of preinvasive breast cancer – Aatish Thennavan
  • RF3-3 (35): A Multi-cohort Comparison of Genomic, Clinical, and AI Models for Recurrence Prediction in Early Breast Cancer – Lajos Pusztai
  • RF3-4 (36): Validation of Quantitative Standardized High Sensitivity (HS)-HER2 as a prognostic factor for outcomes with trastuzumab deruxtecan (T-DXd) for metastatic breast cancer – Paolo Tarantino
  • RF3-5 (37): Pretreatment spatial transcriptomic features associated with response to neoadjuvant HER2-targeted therapy in HER2-positive breast cancer – Emilia Morales
  • RF3-6 (38): Artera Multimodal AI Digital Pathology Identifies Distant Metastasis and Late Recurrence Risk Beyond the Recurrence Score: External Validation in TAILORx – Rima Patel
    RF3-7 (39): Prospective clinical utility trial of PAM50 intrinsic molecular subtyping to inform physician treatment decisions in metastatic breast cancer- Primary results from HARMONY (TBCRC 072) – Yara Abdou

 

Rapid Fire 4

Wednesday, 9 December 2026 | 7 research presentations

  • RF4-1 (40): Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for High-Risk, Early-Stage Triple-Negative Breast Cancer (TNBC): Final Analysis Results in the T2N0 Subgroup From the Phase 3 KEYNOTE-522 Study – Peter Schmid
  • RF4-2 (41): Long-term outcomes after pathological complete response (pCR) to neoadjuvant chemo-immunotherapy (NA-CIO) without adjuvant PD-1/PD-L1 inhibition in early-stage triple negative breast cancer: an individual patient pooled analysis – Stephen J Luen
  • RF4-3 (42): Efficacy and safety of bulumtatug fuvedotin (BFv, 9MW2821), a Nectin-4 antibody-drug conjugate (ADC), in patients with advanced triple-negative breast cancer (aTNBC) previously treated with antibody-drug conjugates (ADCs): a phase Ib dose optimization study (9MW2821-CP103). – Nour Abuhadra
  • RF4-4 (43): Whole-genome sequencing-defined homologous recombination deficiency predicts carboplatin benefit in early triple-negative breast cancer: long-term survival outcome and biomarker analysis of the phase III PEARLY trial (KCSG BR 15-1) – Joohyuk Sohn
  • RF4-5 (44): Phase II Study of Izalontamab Brengitecan (iza-bren) Combined with Toripalimab in Patients with Unresectable Locally Advanced, Recurrent or Metastatic Triple-Negative Breast Cancer (TNBC) – Jian Zhang
  • RF4-6 (45): Safety and preliminary efficacy of SYS6010 monotherapy in patients with HER2-negative, EGFR-expressing breast cancer – Jian Zhang
  • RF4-7 (46): Subtyping-guided addition of bevacizumab to treatment of physician’s choice for previously untreated, advanced, basal-like immune-suppressed triple-negative breast cancer: a randomised, multicentre, phase 3 trial – Linxiaoxi Ma

Rapid Fire 5

Thursday, 10 December 2026 | 7 research presentations

  • RF5-1 (47): Can FAST MRI detect breast cancers missed by mammography for women with average mammographic density attending their first screening mammogram? – results of the interim analysis of the DYAMOND Trial – Lyn Isobel Jones
  • RF5-2 (48): De-escalated Denosumab (Every 12 versus Every 4 Weeks) Maintains Efficacy for Prevention of Symptomatic Skeletal Events in Patients with Bone Metastases: Breast Cancer Stratum from the Randomized Phase-III Non-Inferiority REDUSE Trial (SAKK 96/12) – Andreas Müller
  • RF5-3 (49): Pink! Leben: a randomized controlled trial of an acceptance and commitment therapy-based digital intervention for psychological distress in breast cancer patients across treatment phases – Christian Schem
  • RF5-4 (50): Quality of life for patients aged 40 or older with oestrogen receptor-positive HER2-negative early breast cancer and 0-9 involved axillary lymph nodes within the OPTIMA trial – Janet Audrey Dunn
  • RF5-5 (51): Temperature-controlled hand-foot cooling prevents chemotherapy-induced polyneuropathy (cipn): updated real-world data collection in 600 patients – Athina Kostara
  • RF5-6 (52): The role of estrogen plus progestogen on breast cancer incidence: a systematic review and meta-analysis of randomized clinical trials – Margaret S Pichardo
  • RF5-7 (53): Social drivers, age-at-onset, and later stage at diagnosis in association with aggressive RNA-based breast cancer subtypes among Black women – Sarah C Van Alsten

Rapid Fire 6

Thursday, 10 December 2026 | 7 research presentations

  • RF6-1 (54): Interim event-free survival with peri-operative immune checkpoint inhibition and cryoablation in residual triple-negative breast cancer – Heather L McArthur
  • RF6-2 (55): Breast-mri trial: the paradox of preoperative breast mri – more surgery, no detectable survival benefit in a randomized trial – Bruna S Mota
  • RF6-3 (56): Technical outcomes of node marking and targeted axillary dissection after neoadjuvant chemotherapy in node-positive breast cancer: results from 1295 participants in the ATNEC trial – Amit Goyal
  • RF6-4 (57): Prediction of pathological tumor size in 2,138 breast cancer patients treated with breast-conserving surgery: comparative analysis of preoperative imaging modalities in the prospective multicenter MELODY (EUBREAST-4 / iBRA-NET / AGO-B-062) study – Nikolas Tauber
  • RF6-5 (58): Axillary Radiotherapy as an Alternative to Axillary Lymph Node Dissection in Sentinel Node-Positive Breast CancerPatientsAfter Neoadjuvant Therapy: Three-Year Outcomes from the ADARNAT Pilot Randomized Trial – Amparo Garcia-Tejedor
  • RF6-6 (59): One-week or three-week Adjuvant Radiation in Breast Cancer (OTHAR) – A Phase III Non-Inferiority Randomized controlled Trial- Early outcomes and Acute Toxicity Results – Supriya Mallick
  • RF6-7 (60): Oncological safety of breast-conserving surgery following neo-adjuvant chemotherapy in locally advanced breast cancer: Results from a randomized controlled trial – Ankita Manan Sheth

Rapid Fire 7

Friday, 11 December 2026 | 6 research presentations

  • RF7-1 (61): Treatment discontinuations and patient-reported outcomes in lidERA Breast Cancer: A Phase III trial of giredestrant in patients with estrogen receptor-positive, HER2-negative early breast cancer – Sara A Hurvitz
  • RF7-2 (62): Efficacy and Safety of a 6-Month Pre-mixed Depot formulation, Leuprorelin Mesylate Injection (6M) with Tamoxifen in Premenopausal HR+ Breast Cancer: A Phase III, Randomized, Open-Label, Non-Inferiority Study in China – Jian Zhang
  • RF7-3 (63): I-SPY 2 Endocrine Optimization Pilot (EOP): elagolix vs GnRH agonist as ovarian function suppression (OFS) in premenopausal patients receiving neoadjuvant (Z)-endoxifen for estrogen receptor positive (ER+)/HER2 negative (HER2-) stage 2/3 breast cancer (BC) – Annabelle Duflock
  • RF7-4 (64): A randomised non-comparative phase II study of Adjuvant PALbociclib as an Alternative to CHemotherapy in Elderly patientS with high-risk ER+/HER2- early breast cancer (APPALACHES); EORTC-1745-ETF-BCG – Hans Wildiers
  • RF7-5 (65): Afuresertib and fulvestrant for PIK3CA/AKT1/PTEN-altered, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III part of LAE205INT3101 trial – Pin Zhang
  • RF7-7 (66): Updated Efficacy Results From LEONARDA-2: A Phase III, Randomized, Placebo-Controlled Trial of Lerociclib Plus Letrozole as First-Line Therapy for HR+/HER2- Advanced Breast Cancer – Xichun Hu

Source: Official SABCS program (Checked 17 November 2026).”

Find out more:

SABCS 2026: The Top 10 Breast Cancer Studies to Watch for Potential Practice-Changing Results

Yakup Ergün: Full List of Oral Research Presentations at SABCS 2026